Scholar Rock Holding Corporation (SRRK) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Scholar Rock Holding Corporation (NASDAQ: SRRK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $43.98 (+2.49% 1D, market cap $5.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SRRK ranks #432 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRRK carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGON (CG Oncology Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B) and CRSP (CRISPR Therapeutics AG) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.6%, cap $4.83B). Among the 5-stock peer group, SRRK leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).
Per SRRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001727196), Scholar Rock Holding Corporation generated $1.08B in revenue (+52.6% YoY), -$378.0M in net income, and -$300.6M in free cash flow against $404.3M in total assets and $99.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 13.67 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SRRK currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Clean SEC annual filing review with no major hidden accounting time-bombs.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($47.31) and Max Pain ($46.18) forces dealer call-delta covering toward $64.85.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Scholar Rock Holding Corporation (SRRK) surged +2.49% to $43.98, trading at 49% of its 52-week range ($27.07 – $61.76). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today. Is the current US$44.18 price still grounded in the company’s book va
https://www.federalregister.gov/public-inspection/2026-21718/priority-review-voucher-rare-pediatric-disease-product-isembyld-apitegromab-mstn
CAMBRIDGE, Mass., October 20, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open.
CAMBRIDGE, Mass., October 16, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly h
Scholar Rock has resubmitted its Marketing Authorisation Application to the European Medicines Agency for apitegromab in spinal muscular atrophy, switching to an alternate fill-finish facility that already supported the
CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.
Yahoo Finance coverage on SRRK stock catalysts, institutional flow, and earnings outlook.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +52.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SRRK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SRRK. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Scholar Rock Holding Corporation (SRRK) ranks #432 by composite RQD confidence (41/100, grade D-) and #154 by equity capitalization ($5.23B). Within this direct 5-issuer industry benchmark cohort, SRRK leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SRRK at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SRRK
ACTIVE
Scholar Rock Holding Corporation | D- | 41/100 | — | — | -35.0% | +2.49% | $5.23B | Benchmark Subject |
| CGON CG Oncology Inc. | D- | 42/100 | — | — | -20.8% | +3.39% | $5.49B | /cgon-vs-srrk → |
| CRSP CRISPR Therapeutics AG | D- | 35/100 | — | — | -30.6% | 0.00% | $4.83B | /crsp-vs-srrk → |
| IMVT Immunovant Inc. | D- | 37/100 | — | — | -35.0% | +2.22% | $5.87B | /imvt-vs-srrk → |
| KOD Kodiak Sciences Inc | D+ | 54/100 | — | — | -35.0% | +1.30% | $6.14B | /kod-vs-srrk → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported GAAP revenue of $1.08B (+52.6% vs. FY2024 revenue of $705.8M , and +124.6% cumulative change since FY2023) , GAAP net income of -$378.0M, operating cash flow of -$300.0M, and free cash flow of -$300.6M (-49.5% YoY). On the balance sheet, SRRK closed FY2025 with $404.3M in total assets against $99.7M in total debt (Altman Z-Score: 13.67, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.08B | -$378.0M | -$300.0M | -$300.6M | $404.3M | $99.7M |
| FY2024 (FY) | 2024-12-31 | $705.8M | -$246.0M | -$200.9M | -$201.0M | $474.9M | $50.1M |
| FY2023 (FY) | 2023-12-31 | $479.6M | -$166.0M | -$145.2M | -$145.2M | $2.96B | $692.5M |
As of 2026-11-03, Scholar Rock Holding Corporation (NASDAQ: SRRK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $43.98 (+2.49% 1D, market cap $5.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SRRK ranks #432 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRRK carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGON (CG Oncology Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B) and CRSP (CRISPR Therapeutics AG) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.6%, cap $4.83B). Among the 5-stock peer group, SRRK leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).
Per SRRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001727196), Scholar Rock Holding Corporation generated $1.08B in revenue (+52.6% YoY), -$378.0M in net income, and -$300.6M in free cash flow against $404.3M in total assets and $99.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SRRK last traded at $43.98 (+2.49% on volume of 676,854 shares), positioning the stock -7.04% below its 50-day simple moving average ($47.31) and -8.70% below its 200-day simple moving average ($48.17). Across its 52-week range of $27.07 to $61.76, SRRK sits at the 48.7% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.5% ($40.68 to $47.28).
Scholar Rock Holding Corporation (SRRK) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $43.98 (+2.49% 1D, market capitalization $5.23B).
Scholar Rock Holding Corporation (SRRK) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The reported revenue in the SEC financials is — for each period shown.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported $1.08B in annual revenue (up from $705.8M in FY2024, +52.6% YoY) and -$378.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($479.6M revenue, -$166.0M net income) through FY2025, SRRK scaled operating cash flow to -$300.0M and free cash flow to -$300.6M, backed by $404.3M in total assets against $99.7M in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), SRRK carries a macro regime beta of 1.02 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Scholar Rock Holding Corporation (SRRK) • Click "Debate This Headline" to argue it in the Roar Pit below
Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today. Is the current US$44.18 price still grounded in the company’s book va
https://www.federalregister.gov/public-inspection/2026-21718/priority-review-voucher-rare-pediatric-disease-product-isembyld-apitegromab-mstn
CAMBRIDGE, Mass., October 20, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open.
CAMBRIDGE, Mass., October 16, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly h
Scholar Rock has resubmitted its Marketing Authorisation Application to the European Medicines Agency for apitegromab in spinal muscular atrophy, switching to an alternate fill-finish facility that already supported the
CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular
The forensic balance sheet scores 16/20 with an Altman Z-Score of 13.67 and reported cash rising to $323.5M, giving the company a financial buffer despite operating losses.. When you look under the hood at SRRK, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $61.76. My 12M target is $53.12.
@MultipleCompression Shorting a 7/20 institutional whale-flow stock at $43.90 is dangerous when funds are rotating into Health Care.
With ROIC at -35%, FCF of -$300.6M, and EPS (TTM) of -3.1, the company is consuming cash rather than generating it, and reported revenue is $0.0M.. Look at the math on SRRK: paying 32.0x forward P/E for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $38.63 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: